Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effortSerena Masciari, Judy E. Garber, Deborah Dillon et al.|Breast Cancer Research and Treatment|2012Cited by 189
Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signalingJohanna C. Bendell, S.‐H.I. Ou, Michael S. Gordon et al.|European Journal of Cancer|2020Cited by 27
Abstract LB001: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancersMarianna Koczywas, Sai‐Hong Ignatius Ou, Eric B. Haura et al.|Cancer Research|2021Cited by 16